David Mott Acquires Ardelyx Shares
David Mott bought 39,715 shares of Ardelyx, Inc. on June 16.
Key Points
- David Mott purchased 39,715 shares of Ardelyx, Inc. (ARDX) on June 16, 2026.
- Ardelyx, Inc. trades at $5.84 with a market cap of $1.44 billion and a forward P/E of 11.3.
- Peers like BlackRock and Millennium Management have also adjusted their positions in Ardelyx.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
David Mott made a significant move by acquiring 39,715 shares of Ardelyx, Inc. (NasdaqGM: ARDX) on June 16, 2026. The transaction did not involve a planned purchase, and no specific price or total value was disclosed.
Insider Buying and Selling at Ardelyx, Inc.
Several insiders, including David Mott, increased their holdings in Ardelyx on June 16, 2026. William Bertrand Jr. bought 39,715 shares, while Richard Rodgers and Robert Bazemore each acquired 26,455 shares. These transactions were not part of pre-arranged trading plans.
Other Institutional Activity in Ardelyx, Inc.
BlackRock, Inc. added 25,027 shares to its stake in Ardelyx, bringing its total to 21,164,132 shares valued at approximately $126.77 million. Millennium Management LLC significantly increased its holdings by 5,932,859 shares, now holding 17,842,370 shares worth about $106.88 million. State Street Corp also grew its position by 1,691,968 shares, reaching 13,604,307 shares valued at $81.49 million. On the other hand, Janus Henderson Group PLC reduced its stake by 6,143,458 shares, now holding 8,371,234 shares worth approximately $50.14 million.
Ardelyx, Inc. Stock Up 53.3%
Shares of Ardelyx, Inc. are trading around $5.84. The company has a market capitalization of $1.44 billion and a forward P/E ratio of 11.3. Ardelyx has a beta of 0.576, indicating lower volatility compared to the market. It has seen a 52-week low of $3.49 and a high of $8.40. The stock's 50-day moving average is $6.15, while the 200-day moving average is $6.12.
$ARDX stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Ardelyx reported revenue of $427.68 million with a growth rate of 27.5%. However, the company posted a net margin of -13.6% and a return on equity of -39.5%, indicating challenges in profitability. The next earnings report is expected on August 3, 2026.
Analysts Set New Price Targets
On June 16, 2026, Ladenburg Thalmann assumed coverage of Ardelyx with a "buy" rating and a $16 price target. HC Wainwright & Co. maintained its "buy" rating with an $18 target, while Wedbush also kept a "buy" rating with a $19 target earlier in the year. The consensus among analysts is a "strong buy" with a mean target price of $16.3.
About Ardelyx, Inc.
Ardelyx, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on discovering, developing, and commercializing medicines to address unmet medical needs. The company offers IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis. Led by CEO Michael G. Raab, Ardelyx employs 489 people.
Bottom Line
David Mott's purchase of Ardelyx shares on June 16 highlights ongoing interest in the company. While the 13F filings and insider transactions provide a snapshot of past activity, they may not reflect current positions. Investors often track these moves to gauge confidence in the company's future prospects.
Get Ardelyx, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ARDX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.